Wikipedia -WSS

Wikipedia

author：knowledge 2025-10-01 06:01:11 - browse：83697

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

Alnylam Pharmaceuticals said Thursday that sales of its treatments for rare diseases grew 43% in the second quarter compared to the year-ago period, as the biotech prepares for a key meeting with the Food and Drug Administration in September.

Net product sales in the quarter were $306 million, led by Amvuttra, the company’s RNAi treatment for hereditary ATTR, with sales of $132 million, exceeding Wall Street forecasts. Sales of Onpattro, its older medicine for hereditary ATTR, were $91 million, slightly less than expectations.

The FDA has scheduled a meeting of outside experts on Sept. 13 to discuss the company’s application to expand the indication for Onpattro to include ATTR-CM, a related condition that affects the heart. The FDA decision is due by Oct. 8. An expansion would open a much larger market for the drug than its current approval, which largely targets nerve-related damage.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： In his State of the Union, Biden takes clear aim at 'Big Pharma'

leisure time

WSS

Physician executives need more than on

3 questions for the future of Biden's cancer moonshot

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

Sen. Paul opposes bill to ban Chinese biotechs

FDA authorizes Novavax’s updated Covid

Change Healthcare cyberattack prompts Medicare loan program

knowledge

Wikipedia

hotspot

At least 13 dead in Texas as scorching temps continue

Phenylephrine and the overlooked value of the placebo effect

After affirmative action ruling, medical educators look to 'holistic review'

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

In age of alternative facts, a scholarly course on calling out crap

UnitedHealth quietly bought dozens of outpatient centers

After affirmative action ruling, medical educators look to 'holistic review'

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

Anesthesiologist group: stop taking Ozempic before surgery

Sen. Paul opposes bill to ban Chinese biotechs

leisure time

Change Healthcare cyberattack prompts Medicare loan program

FDA authorizes Novavax’s updated Covid

FDA authorizes Novavax’s updated Covid

Analysis of telehealth claims data suggest service duplication

FDA rejects Alnylam's heart disease treatment over insufficient data

Physician executives need more than on

explore

knowledge

leisure time

entertainment